Ferguson, James J <br/><br/>
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.  [electronic resource] 

 -  American heart journal  Oct 2003 
 - 628-34 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1097-6744 
<br/><br/><label>Standard No.: </label>10.1016/S0002-8703(03)00165-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angina, Unstable<br/>Angioplasty, Balloon, Coronary<br/>Antibodies, Monoclonal--adverse effects<br/>Anticoagulants--adverse effects<br/>Coronary Disease--complications<br/>Drug Therapy, Combination<br/>Enoxaparin--adverse effects<br/>Eptifibatide<br/>Female<br/>Fibrinolytic Agents--adverse effects<br/>Hemorrhage--chemically induced<br/>Heparin, Low-Molecular-Weight--adverse effects<br/>Humans<br/>Immunoglobulin Fab Fragments--adverse effects<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--complications<br/>Peptides--adverse effects<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Syndrome<br/>Thrombolytic Therapy<br/>Tirofiban<br/>Treatment Outcome<br/>Tyrosine--adverse effects